Gresham House Ventures announces its investment into CISIV, which took place last year.
CISIV is a technology business providing electronic data capture, management and analytics to pharma companies and clinical research organisations.
CISIV’s product, Baseline Plus, is a SaaS tool which allows users to design, manage and analyse data collection from real world drug trials, which have become a key focus area for customers, regulators and licensing bodies.
Brendan Gulston, Investment Director at Gresham House said: “We’re thrilled to announce our investment in CISIV. As an innovative company operating in an exciting and specialised market with a strong customer pedigree, they’re exactly the kind of business we look to invest in. We are very excited to be working with Dominic, Ruth and the team to further build on the potential in their product.”